Fluorescence lifetime-based contrast enhancement of indocyanine green-labeled tumors

Anand T. N. Kumar
Stefan A. Carp
Jing Yang
Alana Ross
Zdravka Medarova
Chongzhao Ran
Fluorescence lifetime-based contrast enhancement of indocyanine green-labeled tumors

Anand T. N. Kumar, Stefan A. Carp, Jing Yang, Alana Ross, Zdravka Medarova, and Chongzhao Ran
Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Charlestown, Massachusetts, United States

Abstract. Although the development of tumor-targeted fluorescent probes is a major area of investigation, it will be several years before these probes are realized for clinical use. Here, we report an approach that employs indocyanine-green (ICG), a clinically approved, nontargeted dye, in conjunction with fluorescence lifetime (FLT) detection to provide high accuracy for tumor-tissue identification in vivo (mouse) models of subcutaneous human breast and brain tumors. The improved performance relies on the distinct FLTs of ICG within tumors versus tissue autofluorescence and is further aided by the well-known enhanced permeability and retention of ICG in tumors and the clearance of ICG from normal tissue several hours after intravenous injection. We demonstrate that FLT detection can provide more than 98% sensitivity and specificity, and a 10-fold reduction in error rates compared to intensity-based detection. Our studies suggest the significant potential of FLT for accurate tumor-tissue identification using ICG and other targeted probes under development, both for intraoperative imaging and for ex vivo margin assessment of surgical specimens.

Keywords: fluorescence lifetime; indocyanine green; tumors; time-resolved imaging; optical imaging; margin detection.

Paper 170071LR received Jan. 28, 2017; accepted for publication Mar. 21, 2017; published online Apr. 11, 2017.

A great unmet need in oncologic surgery is the ability to accurately identify tumor-positive margins during surgical resections and to rapidly assess the margin status of resection specimens immediately following surgery. Several ongoing efforts are focused on developing imaging techniques for intraoperative surgical guidance and targeted fluorophores for tumor imaging. While many promising fluorophores have emerged, many of these are either being evaluated at the preclinical stage or are several years from FDA approval and clinical realization. The only fluorescent dyes currently approved for clinical use are fluorescein, indocyanine green (ICG), methylene blue, and 5-aminolevulinic acid. Of these, ICG allows deep tissue imaging due to its longer excitation wavelength. ICG has been evaluated for imaging liver, ovarian, head and neck, and breast cancers, by exploiting the enhanced permeability and retention within the tumor microenvironment. ICG has also been evaluated as a targeted marker in preclinical models using fluorescence lifetime (FLT) to distinguish bound from unbound probes, for example, by conjugation with peptides targeting integrins. However, these probes are still under preclinical evaluation and would need to go through the FDA approval pipeline before clinical translation, since they involve changes in chemical structure from ICG.

Despite these studies and the wide range of possible applications, ICG has not yet been widely adopted clinically in the intraoperative or diagnostic settings. This can be attributed to the fact that significant ICG remains in surrounding tissue even after tumor uptake, resulting in high nonspecific fluorescence immediately following ICG injection and leading to high false-positive rates. Previous clinical imaging studies of breast cancer have found that imaging the extravascular phase of ICG (~25 min after injection) can improve contrast between tumor and normal tissue. However, our measurements indicate that significant ICG remains in normal tissue even during the extravascular phase and is only cleared from tissue beyond 24 h after injection. In addition, we have observed that even after complete ICG clearance from tissue, the intensity of autofluorescence (AF) can be comparable (same order of magnitude) to that of the ICG fluorescence from tumors. Thus, while late imaging beyond 24 h after ICG injection could offer an excellent opportunity for tumor imaging, tissue AF significantly reduces tumor contrast. Most existing clinical optical imaging systems are based on continuous wave (CW) imaging, which detects total fluorescence intensity and does not offer good contrast of ICG fluorescence versus tissue AF. In this letter, we show that time-domain (TD) fluorescence detection can exploit the FLT contrast between tumor-bound ICG and tissue AF (Fig. 1) more than 24 h after ICG injection, significantly enhancing the sensitivity and specificity for identifying tumor tissue in subcutaneous and orthotopic models of breast and brain cancer in living mice. An important advantage of FLT is that it is generally insensitive to experimental conditions, thereby serving as a more robust indicator of ICG versus AF signals than CW intensity.

We used mice with tumors derived from U87 glioma [Figs. 2(a), 2(d), and 2(g)], 4T1 breast [Figs. 2(b), 2(e), and 2(h)], and MDA-MB-231 breast cancer cell lines [Figs. 2(c), 2(f), and 2(i)]. All procedures were performed in accordance with the Massachusetts General Hospital animal welfare guidelines. The glioma and MDA-MB-231 tumors were grown subcutaneously in nu/nu mice and imaged when the tumors reached a size of ~1 to 1.5 cm. The 4T1 tumors were grown orthotopically in the mammary fat pad of BALB/c mice. All the mice (n = 6, 2 per tumor type) were injected IV in the tail vein with 0.12 mg/mL of ICG, dissolved in 5% dimethyl sulfoxide and saline. In all cases, imaging was performed at least 24 h after the ICG injection to ensure complete clearance of ICG from normal tissue. The animals were administered continuous anesthesia (2% isoflurane) during imaging. TD fluorescence was collected in a reflectance mode using a previously described small animal imaging system consisting of a Ti:Sapphire laser for excitation (Spectra Physics, Mai Tai HP; 770-nm excitation; 100-fs pulses; 80-MHz repetition rate, 10
to 20 mW average total power across the illumination field) and a gated intensified CCD camera for detection (LaVision, Picostar, 560 V gain, 100- to 500-ms integration time, 256 × 344 pixels after 4 × 4 hardware binning). Fluorescence was collected using an 800-nm long pass emission filter. The typical acquisition time for a full TD measurement was 10 s.

Figure 2 shows white light images [Figs. 2(a)–2(c)], CW fluorescence images [Figs. 2(d)–2(f)], obtained as the total TD signal at each pixel, and FLT maps [Figs. 2(g)–2(i)] across the illumination area. The FLT maps were obtained by fitting the decay portion of the TD response (as shown in Fig. 1) at each pixel location (2 × 2 binned) to a single exponential decay function. The nonlinear fitting was performed using the MATLAB “fminsearch” function. Note from Fig. 1 that tissue AF exhibits a nonexponential decay that can be fit using a biexponential function. However, for computational efficiency, we analyzed the entire image using a single exponential function, which resulted in a distribution of FLTs across normal tissue, as shown in Figs. 2(j)–2(l). For normal tissue regions with AF, the single exponential fit would result in an “effective” FLT. For the purposes of quantification, we first defined a...
tumor region-of-interest (ROI) based on a visual identification of the tumor surface from the white light images [blue dashed line in Figs. 2(a)–2(f)]. It is clear that while the CW fluorescence [Figs. 2(e)–2(f)] shows a strong nonspecific signal outside the tumor ROI, due to AF, the FLT maps [Figs. 2(e)–2(f)] delineate the tumor boundaries more clearly. We also observed that the FLT for a given tumor type was similar across at least two different mice, to within the FLT estimation error (~5%). It is also seen from Fig. 2 that the mean FLT of ICG within the tumor depends on the tumor type, ranging from 0.45 ns in the 4T1 tumor model to 0.71 ns in the U87 model. This variation could be attributed to variations in the local tumor environment and will be investigated in detail in future work. Irrespective of the underlying cause of the FLT variations between tumor types, the mean FLT of ICG within the tumor ROI for all cases was at least 20% longer than the AF FLT of normal tissue. This FLT difference is readily resolvable using TD imaging.

To quantitatively compare the performance of CW versus FLT for tumor identification, we performed a receiver-operating-characteristic (ROC) analysis by varying the intensity and FLT thresholds, respectively, and computing the sensitivity, specificity, and accuracy. Sensitivity is calculated as the total number of pixels within the tumor area with intensity or FLT above the threshold, divided by the total number of pixels within the tumor. Specificity is the total number of pixels outside the tumor area below the threshold intensity or lifetime/total number of pixels outside the tumor. Accuracy was calculated as follows: $F_1$ score = 2 × sensitivity × specificity / (sensitivity + specificity). Arrows indicate points of highest accuracy/least error.

![Fig. 3](image-url) Normalized distribution of (a) CW intensity and (b) FLT in the tumor (red) and normal tissue (green) for the U87 glioma tumor data in Figs. 2(c) and 2(d). Sensitivity, specificity, and accuracy of thresholding using (c) CW Intensity and (d) FLT. Sensitivity is calculated as the total number of pixels within the tumor area with intensity or lifetime above the threshold/total number of pixels within the tumor. Specificity is the total number of pixels outside the tumor area below the threshold intensity or lifetime/total number of pixels outside the tumor. Accuracy was calculated as follows: $F_1$ score = 2 × sensitivity × specificity / (sensitivity + specificity). Arrows indicate points of highest accuracy/least error.
Fig. 4 ROC curves for the CW and FLT analysis of the glioma tumor data in Figs. 2(f) and 2(g). False-positive rate = 1 − specificity.

of many experimental parameters including excitation intensity and filter leakage.

The goal of the present study was not to identify the origins of the FLT difference between ICG within tumors and tissue AF, but rather to exploit this FLT contrast for enhancing tumor-tissue identification for in-vivo applications. We have observed in control mice that immediately after injection, the ICG FLT is increased in vivo to ∼0.68 ns compared to its in-vitro FLT (∼0.4 ns) in agreement with previous work [20] which attributed the increase in FLT to a change in polarity upon binding to albumin in blood. We have shown that the combination of enhanced ICG retention in tumors, long-time clearance of ICG from normal tissue, and increased FLT compared to surrounding healthy tissue offers a new opportunity for enhancing tumor specificity for clinical applications. The scope of the present study could be extended beyond the use of ICG for tumor identification alone, to enhance the sensitivity of other intraoperative applications of ICG currently in use. The application of FLT contrast for enhanced sensitivity can also extend to other NIR probes under development, including fluorophores that can be specifically labeled for disease targeting. At least two dyes currently in the FDA approval pipeline, IRDye800CW and chlorotoxin-Cy5.5 (tumor paint) [21] allow specific targeting. Probes can also be designed to shift FL upon binding to disease-specific molecular expression allowing an “optical switch” property that indicates the presence or absence of a particular disease. As more of these dyes advance to the clinic, FLT imaging can offer enhanced specificity and sensitivity for various disease applications. Our ongoing work is focused on validation and application of ICG-AF FLT contrast for clinical tumor margin assessment.

Disclosures
No conflicts of interest, financial or otherwise, are declared by the authors.

Acknowledgments
The authors have no relevant financial interests in the manuscript and no other potential conflicts of interest to disclose. This work was supported by the National Institutes of Health under Grant Nos. R01 EB015325 and R01 CA211084, and by the Massachusetts General Hospital ECOR Interim Support Fund.

References

Journal of Biomedical Optics
April 2017 • Vol. 22(4)
040501-4


